Novogen (NASDAQ:KZIA) Given “Buy” Rating at BTIG Research

Novogen (NASDAQ:KZIA)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $40.00 price objective on the stock. BTIG Research’s price target suggests a potential upside of 236.70% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research report on Friday, July 17th. Lake Street Capital assumed coverage on Novogen in a report on Thursday, June 11th. They issued a “buy” rating and a $32.00 price objective on the stock. Finally, Canaccord Genuity Group began coverage on shares of Novogen in a research note on Thursday, August 13th. They set a “buy” rating and a $29.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $27.33.

Novogen Price Performance

Shares of Novogen stock opened at $11.88 on Thursday. The business has a 50 day simple moving average of $13.19 and a two-hundred day simple moving average of $11.65. Novogen has a 12 month low of $4.86 and a 12 month high of $17.40.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.